ESMO 2018 | Renal cell carcinoma trial analysis: current landscape of immunotherapy combinations
Toni Choueiri, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses various immunotherapy combinations showing promising results in early and late stage clinical trials for advanced renal cell carcinoma. Prof. Choueiri presents fascinating results from the JAVELIN Renal 101 study (NCT02684006), a trial comparing the effects of axitinib/avelumab with the current standard, sunitinib, in PD-L1 positive patients, before discussing further trials, an emerging biomarker, and some of the molecular mechnisms underlying the response from an immunotherapy combination. This video was recorded at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.
Get great new content delivered to your inboxSign up